Anupam Rasayan India Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹805.9 crore and net profit of ₹65.0 crore.
- Revenue rose 10.2% year on year and 23.1% sequentially; net profit increased 13.7% year on year and 26.9% sequentially.
- Operating EBITDA margin was approximately 25.1%; ₹50.0 crore of net profit was attributable to owners.
- Results include Bliss GVS Pharma from its acquisition date of September 28, 2026; no exceptional item was reported and limited review reports were unmodified.
